Key Details
Price
$169.80Last Dividend
$0.16Annual Revenue
$2.38 BAnnual EPS
$5.11Annual ROE
10.56%Beta
1.31Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Feb 23, 2017Next split:
N/ARecent split:
May 31, 2006Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Lately, users of Zacks.com have been focusing on Nice (NICE). Therefore, it's important to take a look at what this stock might offer.
PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment offered by NHS England and Wales to prevent hearing loss caused by cisplatin in children and young people aged 1 month to 17 years.
Investors frequently depend on the advice of Wall Street analysts to make choices about buying, selling, or holding stocks. News articles about these analysts from brokerage firms changing their ratings can significantly influence a stock's price.
No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the best features of the Zacks Premium research service.
Lately, users of Zacks.com have been focusing on Nice (NICE). Therefore, it's important to take a look at what this stock might offer.
HOBOKEN, N.J.--(BUSINESS WIRE)-- #Evidencentral--NICE (Nasdaq: NICE) has revealed that the Monterey County District Attorney's Office in California has chosen NICE Justice, an AI-driven tool from NICE's Evidencentral platform. This decision aims to streamline the management of digital evidence in one place and eliminate challenges related to handling such evidence. The Monterey County District Attorney's Office is the fourth in California to adopt this digital transformation for evidence management.
NICE is a leader in customer engagement with its CXone platform. However, it is dealing with tough competition and a drop in revenue in the APAC area.
Nice (NICE) has reached a key support level, making it a potentially strong stock choice based on technical analysis. The stock has also broken through the resistance at the 200-day moving average, indicating a positive long-term trend.
The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons why you should make use of this tool.
The first positive reimbursement decision for LYTENAVA™ has been made globally, with its launch expected in the first half of 2025. This is the only approved eye treatment using bevacizumab for wet age-related macular degeneration (wet AMD) in the EU and UK, potentially helping 40,000 new patients in the UK each year. Outlook Therapeutics, Inc. has received regulatory approval for LYTENAVA™ and NICE has recommended it as a treatment option for wet AMD.
FAQ
- What is the primary business of NICE?
- What is the ticker symbol for NICE?
- Does NICE pay dividends?
- What sector is NICE in?
- What industry is NICE in?
- What country is NICE based in?
- When did NICE go public?
- Is NICE in the S&P 500?
- Is NICE in the NASDAQ 100?
- Is NICE in the Dow Jones?
- When was NICE's last earnings report?
- When does NICE report earnings?
- Should I buy NICE stock now?